WELWYN GARDEN CITY, England and BOSTON, September 12, 2012 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, announces that its President, Dan Grau, will represent the Company at the 5th CNS Partnering and Deal-making conference, which takes place at the Hilton San Francisco Financial District, San Francisco, CA (13-14 September).
On 13 September, Mr Grau will be part of a panel discussion at 2:30pm (PST) entitled "Partnering in the AD, PD and other Cognitive Disorders. How Have Things Changed?"
On 14 September, Mr Grau will give a presentation in the Licensing and Partnering Strategies session at 10:15am (PST) entitled "Back to the Future in Neuroscience: A New Approach to Old (and Validated) Targets."
About Heptares Therapeutics
Heptares discovers and develops new medicines targeting GPCRs (G protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune and Takeda, and we have raised $40M from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.
Heptares is pioneering the application of structure-based drug design to the GPCR superfamily of targets and is focused on creating molecules that modulate high-value, yet historically undruggable or challenging, GPCRs. Our platform incorporates proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time.
Using this approach, we have generated a broad pipeline of drug candidates for the treatment of serious disorders, including Alzheimer's diseas
|SOURCE Heptares Therapeutics|
Copyright©2012 PR Newswire.
All rights reserved